Nakamura Yasuhiro, Otani Setsuya, Otaka Michiro, Shimada Tomoyuki, Takahashi Satsuki, Saito Masahiro, Takahashi Tohru, Komatsu Masahumi, Suzuki Toshie, Okubo Shunji, Hayashi Masato, Sasano Hironobu
Department of Pathology, Tohoku Graduate University School of Medicine, 2-1 Seiryo-machi, Sendai 980-8575, Japan.
Int J Clin Oncol. 2005 Oct;10(5):348-52. doi: 10.1007/s10147-005-0492-y.
We report a patient with gastric small cell carcinoma (SCC) who showed a marked response to neoadjuvant chemotherapy. The patient was a 72-year-old Japanese man who was admitted because of epigastralgia. Subsequent examination revealed the presence of advanced gastric carcinoma in the lesser curvature of the lower body of the stomach, with multiple abdominal lymph node metastases. Endoscopic biopsy specimens from the tumor revealed SCC with moderately differentiated adenocarcinoma. The patient received neoadjuvant chemotherapy consisting of carboplatin (400 mg/m2, for 1 day), epirubicin (27 mg/m2, for 1 day), etoposide (70 mg/m2, for 3 days), and 5-fluorouracil (330 mg/m2, for 11 days). Clinically, the primary tumor and lymph node metastases were markedly reduced. Subsequently the patient underwent curative surgery and was alive without recurrence for more than 3 years after the surgery.
我们报告了一例胃小细胞癌(SCC)患者,该患者对新辅助化疗表现出显著反应。患者为一名72岁的日本男性,因上腹部疼痛入院。随后的检查发现胃体下部小弯侧存在进展期胃癌,并伴有多处腹部淋巴结转移。肿瘤的内镜活检标本显示为SCC合并中度分化腺癌。该患者接受了由卡铂(400 mg/m²,1天)、表柔比星(27 mg/m²,1天)、依托泊苷(70 mg/m²,3天)和5-氟尿嘧啶(330 mg/m²,11天)组成的新辅助化疗。临床上,原发肿瘤和淋巴结转移明显缩小。随后患者接受了根治性手术,术后存活超过3年且无复发。